tbuckley/cabot-search huggingface dataset:
Control of rheumatic fever: how are we doing
Authors: E. A. Mortimer
Journal: JAMA (1977)

The American Heart Association has recently published updated recommendations for the prevention of acute rheumatic fever.<sup>1</sup>These recommendations are essentially the same as those first published 24 years ago<sup>2</sup>; the major differences are a consequence of the development of injectable penicillin G benzathine and of erythromycin, and the demonstration that group A streptococci frequently exhibit resistance to the tetracyclines. The similarities indicate that there have been very few changes in our approach to the control of rheumatic heart disease since it was first shown that acute rheumatic fever can be averted by appropriate treatment of the inciting streptococcal infection and that recurrent rheumatic fever can be prevented by continuous prophylaxis. We still do not know how to predict among those with streptococcal infections who are at risk for rheumatic fever, how to distinguish streptococcal carriers from those with actual infection except in retrospect, or exactly how the<i>Streptococcus</i>
Serologically assessed fragments of type VI collagen are predictors of progression free survival and death in patients with hepatocellular carcinoma
Authors: Diana Julie Leeming, Mette Juul Nielsen, Signe Holm Nielsen, Raj Uchila, Mohammed Eslam, Roslyn Vongsuvanh, David Van Der Poorten, Morten Karsdal, Jacob George
Journal: Journal of Hepatology (2020)
Is it 'oldtimer's disease' or just growing old?
Authors: T. Randall
Journal: JAMA (1991)

The genetic underpinnings of Alzheimer's disease have begun to emerge in recent years, only to reveal that the disease is far more complex, the responsible genes far more elusive, than was hoped. Statistical analyses of pedigrees affected by the disease suggest that at least two chromosomes play a role. The actual genes on these chromosomes, however, are still hidden in stretches of DNA 5 to 10 million base pairs long—a virtual universe left to search. Also emerging is a new way of thinking about the disease. Many experts now suggest that what is called Alzheimer's disease may not be a "disease" at all, but a natural part of the aging process. The theory stems in part from the observation that the brains of elderly persons who are unaffected by Alzheimer's disease also display the hallmark plaque deposits and neurofibrillary tangles found in the brains of patients with Alzheimer's disease, but
Prophylaxis for postoperative deep-vein thrombosis. Synergistic effect of heparin and dihydroergotamine
Authors: V. V. Kakkar
Journal: JAMA (1979)

Randomized clinical trials in 300 patients undergoing major abdominal surgery or hip replacement arthroplasty were performed to investigate the efficacy of dihydroergotamine mesylate, heparin calcium, or a combination of dihydroergotamine with heparin in preventing postoperative deep-vein thrombosis (DVT). The diagnosis of DVT was established by an uptake test using fibrinogen labeled with iodine 125; in patients undergoing hip replacement, phlebography was also employed to confirm or refute the presence of isotopic thrombi. The data indicate that the combination of dihydroergotamine and heparin is more effective than heparin or dihydroergotamine alone in preventing DVT. (<i>JAMA</i>241:39-42, 1979)
Urology
Authors: Fletcher H. Colby
Journal: New England Journal of Medicine (1947)

THE following is a review of recent studies on the use of streptomycin in urologic infections, testicular neoplasms, retroperitoneal tumors and necrotizing renal papillitis.StreptomycinConsiderable progress has been made in recent years in ability to control infections of the urinary tract. Mandelic acid, the sulfonamides and penicillin have played a role in the problem, and during the past year another preparation has become available for this purpose. In 1944 Schatz, Bugie and Waksman1 first described the isolation of a new antibiotic agent that they named "streptomycin." Animal experiments demonstrated the low toxicity of this agent and its effectiveness against . . .
The History of Medicine in the United States. A Collection of Facts and Documents Relating to the History of Medical Science in This Country, from the Earliest English Colonization to the Year 1800. With a Supplemental Chapter on the Discovery of Anesthesia.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Health System Reform
Authors: David M. Eddy
Journal: JAMA (1994)

UNFORTUNATELY, it will. Because that is such an unpleasant thought, it is important to examine each link in the supporting chain of reasoning. As the case for rationing tightens, there will be a tremendous temptation to go back and question the underlying premise. Therefore the first question is: <h3>DO WE REALLY HAVE TO CONTROL COSTS?</h3> Yes, we do. Although virtually everyone agrees that health care costs are a problem, it is worthwhile to review a few of the facts that indicate just how bad the problem is. Begin with the fact that for the last few decades health care costs have been increasing at a rate of about 11.5% a year.<sup>1</sup>This is far faster than other sectors of the economy, with the result that health care has steadily grown as a proportion of the gross domestic product (GDP), from about 5% in 1960 to about 12% in 1990.
Proof arrives: antilipids save lives
Authors: M. F. Goldsmith
Journal: JAMA (1994)

SCANDINAVIAN SKEPTICS carried the day over American enthusiasm. Results of a newly reported study may radically change the way cardiologists care for patients with coronary heart disease. In the United States, only one in four such patients is treated with lipidlowering drugs, despite an ardor for them based on what many European physicians considered flimsy evidence. The prevailing attitude across the ocean nurtured a rigorous scientific study that has produced proof of undeniable efficacy for anticholesterol agents. At the American Heart Association (AHA) annual meeting, in Dallas, Tex, Terje Pedersen, MD, head physician of the Coronary Care Unit at Aker University Hospital, Oslo, Norway, reported the long-awaited results of a study of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin (Zocor, Merck &amp; Co Inc, Whitehouse Station, NJ). In heart attack survivors and persons with angina, this drug reduced not only the risk of heart attack but also the risk of
Editorial: Pregnancy in adolescence.
Journal: BMJ (1975)

Adolescent pregnancy is now a worldwide problem. A study from America shows that 69% and 73%, respectively, of 100 girls under 20 who delivered their babies and 100 who chose abortion had never used any contraception. In 50% of the cases the girl's mother was the head of the household, and 30% of the girls had not completed elementary school. Medicine helps easily on the physical level, but psychologically there are individual differences between cultures and the girls themselves. A good case can be made for special antenatal clinics and abortion clinics for teen-agers. Special efforts should be made after delivery to prevent girls from continuing in the cycle of being and producing social problems.
Mule Is Required for HDAC Inhibitor Function
Journal: Cancer Discovery (2011)

Abstract Major finding: The E3 ubiquitin ligase Mule specifically targets HDAC2 for degradation. Mechanism: Accumulation of HDAC2 blocks p53 acetylation and p53-dependent apoptosis. Impact: Deregulation of Mule expression in cancer cells may affect the response to HDAC inhibitors.
Peculiarities of Behavior. Wandering Mania, Dipsomania, Cleptomania, Pyromania and Allied Impulsive Acts. In two volumes.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3430: TGFBR2 mediated phosphorylation of BUB1 at Ser-318 is required for transforming growth factor-β signaling
Authors: Shyam Nyati, Brandon Gregg, Jiaqi Xu, Grant Young, Lauren Kimmel, Nyati Mukesh, Dipankar Ray, Hongtao Yu, Alnawaz Rehemtulla
Journal: Cancer Research (2019)

Abstract The Ser/Thr kinase BUB1 (budding uninhibited by benzimidazoles-1) is required for efficient signaling by the TGF-β receptor. Recruitment of BUB1 to the activated heteromeric TGF-β-receptor complex including SMAD2 and SMAD3, is required for ligand mediated canonical and non-canonical downstream cascades (Nyati et. al. 2015). In an effort to delineate the structure-function basis for this, we utilized in vitro kinase reactions followed by mass spectrometry to demonstrate that TGFBR2 phosphorylates BUB1 at Serine 318. To elucidate the functional significance of TGFBR2 mediated phosphorylation of BUB1, S318 was substituted with alanine (S318A) or aspartic acid (S318D). Co-immunoprecipitation studies of these phospho-deficient or phospho-mimicking BUB1 mutants with TGFBR1, and SMAD2 revealed that the S318A mutant interacted more efficiently to TGFBR1 and SMAD2 compared to the S318D BUB1. To investigate if the Ser318 residue was involved in mediating BUB1 interaction with TGF-β signaling components, we utilized deletion mutants of BUB1. Our findings reveal that the N-terminal (1-241) and C-terminal (482-723) domains of BUB1 independently interact with SMAD2, SMAD3, TGFBR1, or TGFBR2. The middle domain (241-482) having a S318A mutation interacted efficiently with TGFBR2 while the S318D mutant did not. Additionally, the 241-482 S318D mutant exhibited an increased interaction with SMAD2. Over-expression of 241-482 S318D resulted in a decrease in TGFBR1-TGFBR2 interaction as well as TGFBR1-SMAD2 interaction, suggesting that TGFBR2 mediated BUB1 phosphorylation at S318 maybe the trigger for the dissociation of the activated receptor complex, and therefore a key regulator of TGF-β signaling. Taken together, we show that TGFBR2 phosphorylates BUB1 at Ser318 and propose a model with the following steps: (i) BUB1 is recruited to TGFBR1-TGFBR2 complex in response to ligand, (ii) BUB1 participates in the recruitment of SMAD2/3 to the receptor, (iii) TGFBR2 phosphorylates BUB1 at S318, which triggers the disassembly of the activated complex. Citation Format: Shyam Nyati, Brandon Gregg, Jiaqi Xu, Grant Young, Lauren Kimmel, Nyati Mukesh, Dipankar Ray, Hongtao Yu, Alnawaz Rehemtulla. TGFBR2 mediated phosphorylation of BUB1 at Ser-318 is required for transforming growth factor-β signaling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3430.
Emphysematous cholecystitis. A case report
Authors: S. T. Ruby
Journal: JAMA (1983)

EMPHYSEMATOUS cholecystitis is an uncommon variant of acute cholecystitis, in which the causative agent is a gas-producing bacteria. Recent experience with a patient who manifested emphysematous cholecystitis stimulated this report. <h3>Report of a Case</h3> A 73-year-old man with adult-onset diabetes was admitted with a three-day history of right upper quadrant abdominal pain radiating to his back. His medical history was significant for a myocardial infarction eight years earlier and diabetes, which was controlled by diet. On admission, his temperature was 36.6 °C rectally, vital signs were stable, and an abdominal examination disclosed localized right upper quadrant peritonitis. Laboratory analyses on admission disclosed the following values: WBCs, 15,000/cu mm (84% polymorphonuclear cells, 7% band forms); hematocrit, 47%; ESR, 42 mm/hr; serum amylase, 4 units/L; blood glucose, 302 mg/dL; urinalysis—specific gravity 1.032/5, acetone 2+, WBCs two to five, RBCs two to four; total bilirubin, 1.1 mg/dL; direct bilirubin, 0.3 mg/dL; alkaline phosphatase,
Homoeopathy: medicine or magic?
Journal: BMJ (1991)

guidelines laid down for the profession to follow, and this certainly is an area where public participation and debate must be provided.Nor may the cost-benefit ratio be the only test that is relevant.Some may want to consider the age of the patient, as is done with renal dialysis in Britain.Others may attach weight to the contribution patients make to society or the degree to which they were responsible for their illness.Should haemophiliacs with HIV infection and AIDS be treated any differently from others with the conditions?Should confirmed alcoholics be given an expensive liver transplant if they refuse to give up drink?In Oregon the public expressed interest in 13 social values, but only a few will be incorporated in the process and no one knows yet how it will be done.There remains the problem of deciding how resources should be allocated.Professor Klein is right to stress the need for public and professional involvement, but this will not make the decision process any easier.Many views will be expressed and health authorities will still have the task of reconciling conflicting priorities.Nor can they ignore political realities.Internal market or not, the acute sector is likely to retain the lion's share of funds with the largest amounts still going to the most powerful specialties-those producing the most revenue.If groups like the mentally ill are to be justly treated then central direction combined with ring fenced financing will be needed.Butthe whole process would be greatly facilitated if the NHS were adequately funded.Rationing and resource allocation will be seen to be fair only when Britain devotes as much of its gross national product to health care as does the rest of the European Community.
Continued Cigarette Smoking and the Risk for a Second Heart Attack
Journal: Annals of Internal Medicine (2002)

Summaries for Patients17 September 2002Continued Cigarette Smoking and the Risk for a Second Heart AttackSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-6-200209170-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?People who smoke cigarettes are more likely than nonsmokers to develop blocked blood vessels to the heart and to suffer heart attacks, but these risks decrease to the level of nonsmokers within 2 to 3 years of quitting smoking. Some studies suggest that after a heart attack, persistent smoking does not continue to elevate risk. It is not known whether this impression is correct or, if not, how fast the potential benefits of quitting occur.Who was studied?2619 members of a large health maintenance organization (HMO). All ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Smoking Status and Risk for Recurrent Coronary Events after Myocardial Infarction.” It is in the 17 September 2002 issue of Annals of Internal Medicine (volume 137, pages 494-500). The authors are TD Rea, SR Heckbert, RC Kaplan, NL Smith, RN Lemaitre, and BM Psaty.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSmoking Status and Risk for Recurrent Coronary Events after Myocardial Infarction Thomas D. Rea , Susan R. Heckbert , Robert C. Kaplan , Nicholas L. Smith , Rozenn N. Lemaitre , and Bruce M. Psaty Metrics 17 September 2002Volume 137, Issue 6Page: I-34KeywordsBlood vesselsHealth maintenance organizationsHeartHospitalizationsLongitudinal studiesMyocardial infarctionOutpatient clinicsRisk managementSmoking cessationSmoking habits ePublished: 17 September 2002 Issue Published: 17 September 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Yersinia Enterocolitica
Authors: Timothy L. Cover, Robert C. Aber
Journal: New England Journal of Medicine (1989)

YERSINIA ENTEROCOLITICA is rapidly emerging worldwide as an enteric pathogen associated with a wide spectrum of clinical and immunologic manifestations. The clinical illness caused by this pathogen ranges from self-limited enterocolitis to potentially fatal systemic infection; post-infection manifestations include erythema nodosum and reactive arthritis. The organism was first described by Schleifstein and Coleman in 1939 as "an unidentified microorganism resembling Bacterium lignieri and Pasteurella pseudotuberculosis, and pathogenic for man."1 Isolates were variously named Bacterium enterocoliticum, P. X, P. pseudotuberculosis type b, Germe X, and P. pseudotuberculosis X, until 1964, when Frederiksen proposed the name Yersinia enterocolitica.2 In . . .
Book Review Aftereffects of Brain Injuries in War: Their evaluation and treatment, and the application of psychologic methods in the clinic . By Kurt Goldstein, M.D. With a foreword by D. Denny-Brown, M.D. 8°, cloth, 244 pp., with 46 illustrations and 2 plates. New York: Grune and Stratton, 1942. $4.00.
Journal: New England Journal of Medicine (1943)
Medical and Health Information Directory: A Guide to More Than 40,000 Associations, Agencies, Companies, Institutions, Research Centers, Hospitals, Clinics, Treatment Centers, Educational Programs, Publications, Audiovisuals, Data Banks, Libraries, and Informatiqn Services in Clinical Medicine, Basic BioMedical Sciences, and the Technological and SocioEconomic Aspects of Health Care.
Journal: Annals of Internal Medicine (1989)
From the Congressional Office of Technology Assessment
Authors: J. Eden
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manuel pratique de dermatologie: Le diagnostic, la peau et ses réactions, thérapeutique, les dermatoses.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Childhood Leukemias
Authors: C H Pui
Journal: New England Journal of Medicine (1995)

The childhood leukemias are a study in contrasts. Acute lymphoblastic leukemia (ALL) is diagnosed in approximately 2000 children in the United States each year, whereas acute myeloid leukemia (AML) is diagnosed in only about 500 children, and chronic myeloid leukemia (CML) in fewer than 100. Chronic lymphocytic leukemia (CLL), one of the most common leukemias in adults, seldom occurs in children. Current chemotherapeutic regimens cure as many as 70 percent of children with ALL (Figure 1)14 but only 30 to 40 percent of those with AML,510 and they are ineffective against CML without allogeneic bone marrow transplantation.11 Our . . .